Botulinum toxin type A for facial wrinkles

Keyphrases

• Confidence Interval 100%
• Facial Wrinkles 100%
• Botulinum Neurotoxin (BoNT) 100%
• OnabotulinumtoxinA 85%
• Risk Ratio 80%
• Success Rate 45%
• Major Adverse Events 40%
• Placebo 35%
• Adverse Events 30%
• Randomized Controlled Trial 15%
• DaxibotulinumtoxinA 15%
• Ptosis 15%
• Treatment Duration 10%
• Risk of Bias 10%
• Strabismus 10%
• Event Risk 10%
• Glabella 10%
• Sensory Disorders 10%
• Participant Assessment 10%
• Eyelid 10%
• Certainty of Evidence 10%
• High Failure Rate 5%
• Search Methods 5%
• Selection Criteria 5%
• Low Risk 5%
• Methodological Procedures 5%
• MEDLINE 5%
• Embase 5%
• Absence of Evidence 5%
• Overall Risk 5%
• Active Control 5%
• Number of Cycles 5%
• One-cycle 5%
• Commercially Available 5%
• Between-group 5%
• Treatment Effect 5%
• Two-region 5%
• Moderate to Severe 5%
• Cochrane 5%
• Cochrane Review 5%
• Eyelid Ptosis 5%
• Small number of Studies 5%
• PrabotulinumtoxinA 5%
• Crow's Feet 5%
• Private Office 5%
• 2-cycles 5%
• Low-to-moderate 5%
• Event Duration 5%
• Facial Regions 5%
• Treatment Cycle 5%
• Heterogeneous Studies 5%
• Comparison-based 5%
• Day Clinic 5%
• Duration of Effect 5%
• Physician Assessment 5%
• Full Face 5%
• Perioral 5%
• Hyaluronic Acid 5%
• Effectiveness Outcomes 5%
• Forehead 5%

Neuroscience

• Botulinum Toxin 100%
• Placebo 77%
• Randomized Controlled Trial 33%
• Ptosis 33%
• Strabismus 22%
• Ptosis (Eyelid) 22%
• Sensation Disorder as Neurologic Manifestation 22%
• Face 11%
• Hyaluronic Acid 11%
• Eyelid 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Botulinum Toxin A 100%
• Adverse Event 46%
• Placebo 23%
• Randomized Controlled Trial 10%
• Sensory Dysfunction 6%
• Strabismus 6%
• Ptosis (Eyelid) 6%
• Hyaluronic Acid 3%